Login
Evidence Feed
About
Conferences
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
IDH1 mutation
i
Other names:
HEL-216, HEL-S-26, Epididymis Luminal Protein 216, Isocitrate Dehydrogenase 1 (NADP+), Epididymis Secretory Protein Li 26, IDH1, Isocitrate Dehydrogenase (NADP(+)) 1, Isocitrate Dehydrogenase 1 (NADP+), Soluble
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
3417
Related biomarkers:
Expression
Mutation
Others
‹
›
Associations
News
Twitter
Trials
Reset Filters
VERI cancer hierarchy
x
x
x
x
IDH1 mutation
Acute Myelogenous Leukemia
IDH1 mutation
Acute Myelogenous Leukemia
ivosidenib
Sensitive: A1 - Approval
ASCO 2023 - 4 days (New B)
ivosidenib
Sensitive
:
A1
ASCO 2023 - 4d
ivosidenib
Sensitive: A1 - Approval
ASCO 2023 - 4 days
ivosidenib
Sensitive
:
A1
ASCO 2023 - 4 days - (New B)
IDH1 mutation
Glioma
IDH1 mutation
Glioma
PRT811
Sensitive: C3 – Early Trials
ASCO 2023 - 4 days (New C3)
PRT811
Sensitive
:
C3
ASCO 2023 - 4d
PRT811
Sensitive: C3 – Early Trials
ASCO 2023 - 4 days
PRT811
Sensitive
:
C3
ASCO 2023 - 4 days - (New C3)
IDH1 mutation
Acute Myelogenous Leukemia
IDH1 mutation
Acute Myelogenous Leukemia
venetoclax
Sensitive: A2 - Guideline
EHA 2023 - 2 weeks (New C3)
venetoclax
Sensitive
:
A2
EHA 2023 - 2wk
venetoclax
Sensitive: A2 - Guideline
EHA 2023 - 2 weeks
venetoclax
Sensitive
:
A2
EHA 2023 - 2 weeks - (New C3)
IDH1 mutation
Acute Myelogenous Leukemia
IDH1 mutation
Acute Myelogenous Leukemia
olutasidenib
Sensitive: A1 - Approval
EHA 2023 - 2 weeks (New C3)
olutasidenib
Sensitive
:
A1
EHA 2023 - 2wk
olutasidenib
Sensitive: A1 - Approval
EHA 2023 - 2 weeks
olutasidenib
Sensitive
:
A1
EHA 2023 - 2 weeks - (New C3)
IDH1 mutation
Myelodysplastic Syndrome
IDH1 mutation
Myelodysplastic Syndrome
ivosidenib
Sensitive: C1 - Off-label
EHA 2023 - 2 weeks (New C3)
ivosidenib
Sensitive
:
C1
EHA 2023 - 2wk
ivosidenib
Sensitive: C1 - Off-label
EHA 2023 - 2 weeks
ivosidenib
Sensitive
:
C1
EHA 2023 - 2 weeks - (New C3)
IDH1 mutation
Cholangiocarcinoma
IDH1 mutation
Cholangiocarcinoma
ivosidenib
Sensitive: A1 - Approval
ivosidenib
Sensitive
:
A1
ivosidenib
Sensitive: A1 - Approval
ivosidenib
Sensitive
:
A1
IDH1 mutation
Astrocytoma
IDH1 mutation
Astrocytoma
temozolomide
Sensitive: A2 - Guideline
temozolomide
Sensitive
:
A2
temozolomide
Sensitive: A2 - Guideline
temozolomide
Sensitive
:
A2
IDH1 mutation
Sarcoma
IDH1 mutation
Sarcoma
ivosidenib
Sensitive: A2 - Guideline
ivosidenib
Sensitive
:
A2
ivosidenib
Sensitive: A2 - Guideline
ivosidenib
Sensitive
:
A2
IDH1 mutation
Astrocytoma
IDH1 mutation
Astrocytoma
PCV
Sensitive: A2 - Guideline
PCV
Sensitive
:
A2
PCV
Sensitive: A2 - Guideline
PCV
Sensitive
:
A2
IDH1 mutation
Astrocytoma
IDH1 mutation
Astrocytoma
cisplatin
Sensitive: A2 - Guideline
cisplatin
Sensitive
:
A2
cisplatin
Sensitive: A2 - Guideline
cisplatin
Sensitive
:
A2
IDH1 mutation
Astrocytoma
IDH1 mutation
Astrocytoma
carboplatin
Sensitive: A2 - Guideline
carboplatin
Sensitive
:
A2
carboplatin
Sensitive: A2 - Guideline
carboplatin
Sensitive
:
A2
IDH1 mutation
Astrocytoma
IDH1 mutation
Astrocytoma
etoposide IV
Sensitive: A2 - Guideline
etoposide IV
Sensitive
:
A2
etoposide IV
Sensitive: A2 - Guideline
etoposide IV
Sensitive
:
A2
IDH1 mutation
Astrocytoma
IDH1 mutation
Astrocytoma
bevacizumab
Sensitive: A2 - Guideline
bevacizumab
Sensitive
:
A2
bevacizumab
Sensitive: A2 - Guideline
bevacizumab
Sensitive
:
A2
IDH1 mutation
Astrocytoma
IDH1 mutation
Astrocytoma
carmustine
Sensitive: A2 - Guideline
carmustine
Sensitive
:
A2
carmustine
Sensitive: A2 - Guideline
carmustine
Sensitive
:
A2
IDH1 mutation
Astrocytoma
IDH1 mutation
Astrocytoma
lomustine
Sensitive: A2 - Guideline
lomustine
Sensitive
:
A2
lomustine
Sensitive: A2 - Guideline
lomustine
Sensitive
:
A2
IDH1 mutation
Glioma
IDH1 mutation
Glioma
temozolomide gel
Sensitive: B - Late Trials
temozolomide gel
Sensitive
:
B
temozolomide gel
Sensitive: B - Late Trials
temozolomide gel
Sensitive
:
B
IDH1 mutation
Acute Myelogenous Leukemia
IDH1 mutation
Acute Myelogenous Leukemia
gilteritinib
Resistant: B - Late Trials
gilteritinib
Resistant
:
B
gilteritinib
Resistant: B - Late Trials
gilteritinib
Resistant
:
B
IDH1 mutation
Glioma
IDH1 mutation
Glioma
temozolomide
Sensitive: B - Late Trials
temozolomide
Sensitive
:
B
temozolomide
Sensitive: B - Late Trials
temozolomide
Sensitive
:
B
IDH1 mutation
Glioma
IDH1 mutation
Glioma
PCV
Sensitive: B - Late Trials
PCV
Sensitive
:
B
PCV
Sensitive: B - Late Trials
PCV
Sensitive
:
B
IDH1 mutation
Glioma
IDH1 mutation
Glioma
S95032
Sensitive: B - Late Trials
S95032
Sensitive
:
B
S95032
Sensitive: B - Late Trials
S95032
Sensitive
:
B
IDH1 mutation
Glioma
IDH1 mutation
Glioma
ivosidenib
Sensitive: C1 - Off-label
ivosidenib
Sensitive
:
C1
ivosidenib
Sensitive: C1 - Off-label
ivosidenib
Sensitive
:
C1
IDH1 mutation
Glioblastoma
IDH1 mutation
Glioblastoma
temozolomide
Sensitive: C2 – Inclusion Criteria
temozolomide
Sensitive
:
C2
temozolomide
Sensitive: C2 – Inclusion Criteria
temozolomide
Sensitive
:
C2
IDH1 mutation
Glioblastoma
IDH1 mutation
Glioblastoma
NEO100
Sensitive: C2 – Inclusion Criteria
NEO100
Sensitive
:
C2
NEO100
Sensitive: C2 – Inclusion Criteria
NEO100
Sensitive
:
C2
IDH1 mutation
Glioma
IDH1 mutation
Glioma
TG02
Sensitive: C3 – Early Trials
TG02
Sensitive
:
C3
TG02
Sensitive: C3 – Early Trials
TG02
Sensitive
:
C3
IDH1 mutation
Acute Myelogenous Leukemia
IDH1 mutation
Acute Myelogenous Leukemia
cytarabine/daunorubicin liposomal formulation
Sensitive: C3 – Early Trials
cytarabine / daunorubicin liposomal formulation
Sensitive
:
C3
cytarabine/daunorubicin liposomal formulation
Sensitive: C3 – Early Trials
cytarabine / daunorubicin liposomal formulation
Sensitive
:
C3
IDH1 mutation
Acute Myelogenous Leukemia
IDH1 mutation
Acute Myelogenous Leukemia
venetoclax + ABBV-621
Sensitive: C3 – Early Trials
venetoclax + ABBV-621
Sensitive
:
C3
venetoclax + ABBV-621
Sensitive: C3 – Early Trials
venetoclax + ABBV-621
Sensitive
:
C3
IDH1 mutation
Acute Myelogenous Leukemia
IDH1 mutation
Acute Myelogenous Leukemia
venetoclax + ivosidenib
Sensitive: C3 – Early Trials
venetoclax + ivosidenib
Sensitive
:
C3
venetoclax + ivosidenib
Sensitive: C3 – Early Trials
venetoclax + ivosidenib
Sensitive
:
C3
IDH1 mutation
Glioblastoma
IDH1 mutation
Glioblastoma
pembrolizumab
Resistant: C3 – Early Trials
pembrolizumab
Resistant
:
C3
pembrolizumab
Resistant: C3 – Early Trials
pembrolizumab
Resistant
:
C3
IDH1 mutation
Acute Myelogenous Leukemia
IDH1 mutation
Acute Myelogenous Leukemia
CFI-400945
Sensitive: C3 – Early Trials
CFI-400945
Sensitive
:
C3
CFI-400945
Sensitive: C3 – Early Trials
CFI-400945
Sensitive
:
C3
IDH1 mutation
Acute Myelogenous Leukemia
IDH1 mutation
Acute Myelogenous Leukemia
venetoclax + midostaurin
Resistant: C3 – Early Trials
venetoclax + midostaurin
Resistant
:
C3
venetoclax + midostaurin
Resistant: C3 – Early Trials
venetoclax + midostaurin
Resistant
:
C3
IDH1 mutation
Acute Myelogenous Leukemia
IDH1 mutation
Acute Myelogenous Leukemia
venetoclax + gilteritinib
Resistant: C3 – Early Trials
venetoclax + gilteritinib
Resistant
:
C3
venetoclax + gilteritinib
Resistant: C3 – Early Trials
venetoclax + gilteritinib
Resistant
:
C3
IDH1 mutation
Acute Myelogenous Leukemia
IDH1 mutation
Acute Myelogenous Leukemia
venetoclax + sorafenib
Resistant: C3 – Early Trials
venetoclax + sorafenib
Resistant
:
C3
venetoclax + sorafenib
Resistant: C3 – Early Trials
venetoclax + sorafenib
Resistant
:
C3
IDH1 mutation
Chronic Myelomonocytic Leukemia
IDH1 mutation
Chronic Myelomonocytic Leukemia
venetoclax
Sensitive: C3 – Early Trials
venetoclax
Sensitive
:
C3
venetoclax
Sensitive: C3 – Early Trials
venetoclax
Sensitive
:
C3
IDH1 mutation
Glioma
IDH1 mutation
Glioma
BAY1436032
Sensitive: C3 – Early Trials
BAY1436032
Sensitive
:
C3
BAY1436032
Sensitive: C3 – Early Trials
BAY1436032
Sensitive
:
C3
IDH1 mutation
Anaplastic Astrocytoma
IDH1 mutation
Anaplastic Astrocytoma
PCV
Sensitive: C3 – Early Trials
PCV
Sensitive
:
C3
PCV
Sensitive: C3 – Early Trials
PCV
Sensitive
:
C3
IDH1 mutation
Sarcoma
IDH1 mutation
Sarcoma
olaparib
Sensitive: C3 – Early Trials
olaparib
Sensitive
:
C3
olaparib
Sensitive: C3 – Early Trials
olaparib
Sensitive
:
C3
IDH1 mutation
Myelodysplastic Syndrome
IDH1 mutation
Myelodysplastic Syndrome
venetoclax + ivosidenib
Sensitive: C3 – Early Trials
venetoclax + ivosidenib
Sensitive
:
C3
venetoclax + ivosidenib
Sensitive: C3 – Early Trials
venetoclax + ivosidenib
Sensitive
:
C3
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login